{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:11:44Z","timestamp":1762521104419},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,10,26]],"date-time":"2006-10-26T00:00:00Z","timestamp":1161820800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharm World Sci"],"published-print":{"date-parts":[[2006,10,31]]},"DOI":"10.1007\/s11096-006-9037-3","type":"journal-article","created":{"date-parts":[[2006,10,25]],"date-time":"2006-10-25T08:22:07Z","timestamp":1161764527000},"page":"215-221","source":"Crossref","is-referenced-by-count":11,"title":["Are higher vancomycin doses needed in venticle-external shunted patients?"],"prefix":"10.1007","volume":"28","author":[{"given":"Meritxell","family":"Pujal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Soy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carles","family":"Codina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Ribas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,10,26]]},"reference":[{"key":"9037_CR1","unstructured":"Farreras P, Rozman C. Medicina interna, vol II, XIV Ed. Harcourt, S.A., Madrid. ISBN 84-8174-359-3. 2000;1645, 1709\u201310"},{"key":"9037_CR2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/BF00271135","volume":"3","author":"M Ammirati","year":"1987","unstructured":"Ammirati M, Raimondi AJ. Cerebrospinal fluid shunt infections in children. A study on the relationship between the etiology of hydrocephalus, age at the time of shunt placement and infection rate. Child's Nerv Sys 1987;3:106\u20139","journal-title":"Child's Nerv Sys"},{"issue":"Suppl. A","key":"9037_CR3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/jac\/34.suppl_A.75","volume":"34","author":"R Bayston","year":"1994","unstructured":"Bayston R. Hydrocephalus shunt infections. J Antimicrob Chemother 1994; 34(Suppl. A):75\u201384","journal-title":"J Antimicrob Chemother"},{"key":"9037_CR4","doi-asserted-by":"crossref","first-page":"875","DOI":"10.3171\/jns.1992.77.6.0875","volume":"77","author":"M Choux","year":"1992","unstructured":"Choux M, Genitori L, Lang D, Lena G. Shunt implantation: reducing the incidence of shunt infection. J Neurosurg 1992; 77:875\u201380","journal-title":"J Neurosurg"},{"key":"9037_CR5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/0090-3019(88)90013-4","volume":"29","author":"RG Ellenbogen","year":"1988","unstructured":"Ellenbogen RG, Goldmann DA, Winston KR. Group B Streptococcal infections of the central nervous system in infants with myelomeningocele. Surg Neurol 1988;29:237\u201342","journal-title":"Surg Neurol"},{"key":"9037_CR6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1055\/s-2008-1071349","volume":"23","author":"M Vinchon","year":"1992","unstructured":"Vinchon M, Vallee L, Prin L, Desreumaux P, Dhellemmes P. Cerebro-spinal fluid eosinophilia in shunt infections. Neuropediatrics 1992;23:235\u201340","journal-title":"Neuropediatrics"},{"issue":"2","key":"9037_CR7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.surneu.2003.11.014","volume":"62","author":"JJ Bafeltowska","year":"2004","unstructured":"Bafeltowska JJ, Buszman E, Mandat KM, Hawranek JK. Therapeutic vancomycin monitoring in children with hydrocephalus during treatment of shunt infections. Surg Neurol 2004 Aug;62(2):142","journal-title":"Surg Neurol"},{"issue":"2","key":"9037_CR8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.3171\/jns.1999.90.2.0274","volume":"90","author":"M Bourgeois","year":"1999","unstructured":"Bourgeois M, Sainte-Rose C, Cinalli G, Maixner W, Malucci C, Zera M, et al. Epilepsy in children with shunted hydrocephalus. J Neurosurg 1999 Feb;90(2):274\u201381","journal-title":"J Neurosurg"},{"key":"9037_CR9","unstructured":"Bennett DR, editor. Drug evaluations subscription. Chicago, IL: American Medical Association, Winter 1992"},{"key":"9037_CR10","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/BF01060893","volume":"9","author":"LB Sheiner","year":"1981","unstructured":"Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharmaceut 1981; 9:503\u201312","journal-title":"J Pharmacokinet Biopharmaceut"},{"issue":"2","key":"9037_CR11","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00007691-199604000-00006","volume":"18","author":"MM Fernandez de Gatta","year":"1996","unstructured":"Fernandez de Gatta MM, Fruns I, Calvo MV, Lanao JM, Dominguez-Gil A. Influence of pharmacokinetic model on vancomycin peak concentration targets. Ther Drug Monit 1996 Apr;18(2):145\u20138","journal-title":"Ther Drug Monit"},{"issue":"9","key":"9037_CR12","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1128\/AAC.36.9.1852","volume":"36","author":"I Odenholt-Tornqvist","year":"1992","unstructured":"Odenholt-Tornqvist I, L\u00f6wdin E, Cars C. Postantibiotic sub-MIC effects of vancomycin, roxithromycin, sparfloxacin, and amikacin. Antimicrob Agents Chemother. 1992 sep;36(9):1852\u20138","journal-title":"Antimicrob Agents Chemother"},{"key":"9037_CR13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2174\/157339806775486218","volume":"2","author":"D Soy","year":"2006","unstructured":"Soy D, Badia JR, Torres A. Antibiotic Dosage Regimens in Respiratory Tract Infections in the pharmacokinetic\/pharmacodynamic era. Curr Respiratory Med Rev 2006;2:89\u201397","journal-title":"Curr Respiratory Med Rev"},{"key":"9037_CR14","doi-asserted-by":"crossref","unstructured":"Healy DP, Polk RE, Garson ML, Rock DT, Comstock TJ, Comparison of steady-state pharmacokinetics of two dosage regimens of vancomycin in normal volunteers. Antimicrob Agents Chemother 1987 Mar;31(3):393\u20137","DOI":"10.1128\/AAC.31.3.393"},{"key":"9037_CR15","doi-asserted-by":"crossref","unstructured":"Pryka RD, Rodvold KA, Garrison M, Rotschafer JC. Individualizing vancomycin dosage regimes: one- versus two-compartment Bayesian models. Ther Drug Monit 1989; 11:450\u20134","DOI":"10.1097\/00007691-198907000-00013"},{"key":"9037_CR16","doi-asserted-by":"crossref","unstructured":"Albrecht LM, Rybak MJ, Boike SC, Pancorbo S. Comparison of serum sampling methods for determining vancomycin dosage regimes. Ther Drug Monit 1988;10:85\u201390","DOI":"10.1097\/00007691-198810010-00015"},{"key":"9037_CR17","doi-asserted-by":"crossref","unstructured":"Walson PD. Therapeutic drug monitoring in special populations. Clin Chem 1998;44(2):415\u20139","DOI":"10.1093\/clinchem\/44.2.415"},{"key":"9037_CR18","unstructured":"Evans WE, Schentag JJ, Jusko WJ. Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Spokane, Applied Therapeutics, Inc. 1992"},{"issue":"5","key":"9037_CR19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2165\/00003088-199324050-00002","volume":"24","author":"P Reetze-Bonorden","year":"1993","unstructured":"Reetze-Bonorden P, Bohler J, Keller E. Drug dosage in patients during continuous renal replacement therapy. Pharmacokinetic and therapeutic considerations. Clin Pharmacokinet 1993 May;24(5):362\u201379","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"9037_CR20","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/j.1365-2125.2004.02143.x","volume":"58","author":"ME DelDot","year":"2004","unstructured":"DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol 2004 Sep;58(3):259\u201368","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"9037_CR21","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1128\/AAC.32.6.848","volume":"32","author":"KA Rodvold","year":"1988","unstructured":"Rodvold KA, Blum RA, Fischer JH, Zokufa HZ, Rotschafer JC, Crossley KB, et\u00a0al. Vancomycin pharmacokinetics in patients with various degrees of renal function. Antimicrob Agents Chemother 1988 Jun;32(6):848\u201352","journal-title":"Antimicrob Agents Chemother"},{"key":"9037_CR22","first-page":"297","volume":"10","author":"RE PachoreK","year":"1991","unstructured":"PachoreK RE, Wood F. Vancomycin half-life in a patient with hepatic and renal dysfunction. Clin Pharm 1991; 10:297\u2013300","journal-title":"Clin Pharm"},{"issue":"3","key":"9037_CR23","first-page":"1","volume":"37","author":"J Soto","year":"1992","unstructured":"Soto J, Alsar MJ, Sacristan JA. Initial dosage of vancomycin in neutropenic hematologic patients. Sangre (Barc) 1992 Jun; 37(3):181\u20134","journal-title":"Sangre (Barc)"},{"issue":"1","key":"9037_CR24","first-page":"28[A47]","volume":"22","author":"R Tom\u00e1s","year":"2000","unstructured":"Tom\u00e1s R, Soy D, Garc\u00eda-Pel\u00e1ez M, Cardenete J, Quintana E, Mangues MA. High dose requirements of vancomycin in multiple trauma adult patients in intensive care units [Abstract]. Pharm World Sci 2000;22(1):28 [A47]","journal-title":"Pharm World Sci"},{"issue":"3","key":"9037_CR25","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/jac\/45.3.329","volume":"45","author":"F Pea","year":"2000","unstructured":"Pea F, Porreca L, Baraldo M, Furlanut M. High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures. J Antimicrob Chemother 2000 Mar;45(3):329\u201335","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"9037_CR26","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1128\/AAC.34.5.792","volume":"34","author":"MJ Rybak","year":"1990","unstructured":"Rybak MJ, Albrecht LM, Berman JR, Warbasse LH, Svensson CK. Vancomycin pharmacokinetics in burn patients and intravenous drug abusers. Antimicrob Agents Chemother 1990 May;34(5):792\u20135","journal-title":"Antimicrob Agents Chemother"},{"issue":"34","key":"9037_CR27","first-page":"1554","volume":"23","author":"JM Conil","year":"1994","unstructured":"Conil JM, Favarel H, Laguerre J, Brouchet A, Chabanon G, Cazal L, et\u00a0al. Continuous administration of vancomycin in patients with severe burns. Presse Med 1994 Nov 5; 23(34):1554\u20138","journal-title":"Presse Med"}],"container-title":["Pharmacy World & Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-006-9037-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11096-006-9037-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-006-9037-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,18]],"date-time":"2020-04-18T19:15:46Z","timestamp":1587237346000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11096-006-9037-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,26]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,10,31]]}},"alternative-id":["9037"],"URL":"https:\/\/doi.org\/10.1007\/s11096-006-9037-3","relation":{},"ISSN":["0928-1231","1573-739X"],"issn-type":[{"value":"0928-1231","type":"print"},{"value":"1573-739X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,26]]}}}